RRx-001 for Reducing Oral Mucositis in Patients Receiving Chemotherapy and Radiation for Head and Neck Cancer

Recruiting

Phase 2

RRx-001RRx-001 for Reducing Oral Mucositis in Patients Receiving Chemotherapy and Radiation for Head and Neck Cancer

Sponsor:

EpicentRx, Inc.

Code:

NCT05966194

Conditions

Oral Mucositis

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

RRx-001

Intensity Modulated Radiation Therapy (IMRT)

Cisplatin for injection 100 mg/m2

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2025-03-31. This information was provided to ClinicalTrials.gov by EpicentRx, Inc. on 2024-11-15.